Linda Fogelstrand
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Linda Fogelstrand has a total of 268 co-authors. Here are the top co-authors by number of shared publications:
- Gisela Barbany
Karolinska Institutet
14 shared publications - Vladimir Lazarevic
Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden
14 shared publications - Helena Ågerstam
Lund University
12 shared publications - Lucia Cavelier
Karolinska Institutet
12 shared publications - Martin Höglund
Department of Medical Sciences, Uppsala University, Uppsala, Sweden
12 shared publications - Martin Jädersten
Center for Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden
12 shared publications
Latest Publications
- Open Access
Whole-genome sequencing enables improved AML diagnostics and refines assessment of TP53 allelic state and complex karyotype
Accurate genetic characterization is central to modern acute myeloid leukemia (AML) diagnostics, yet current standard-of-care (SoC) testing relies on multiple complementary assays. We compared paired tumor-normal whole-genome sequencing (WGS) with SoC diagnostics in a population-based cohort of 109 adult AML patients, assessing variant detection, disease classification according to ICC 2022 and WHO 2022, and risk stratification according to ELN 2022. WGS showed high concordance with SoC across variant classes. When considering all reported SoC variants together with high-confidence WGS variants as true positives, WGS showed equal to higher sensitivity than SoC for single-nucleotide variants and small insertions/deletions (97% vs 92%), structural variants (SVs; 100% vs 87%), and copy-number alterations (CNAs; 88.5% both). WGS identified clinically important lesions missed by SoC in 16 cases (15%), including FLT3-ITDs and KMT2A, NUP98 and MECOM rearrangements. Classification and risk assignments were 95-96% concordant, with WGS-driven reclassifications in 4-5% of cases, primarily through detection of cryptic SVs and myelodysplasia-related lesions. Integrated analysis of genomic alterations, including copy-neutral loss-of-heterozygosity, refined TP53 allelic state assessment and demonstrated increased genomic complexity in AML with biallelic TP53 alterations. We developed a supervised machine-learning model for complex karyotype (CK) probability, based on WGS-derived copy-number and SV burden, enabling automated identification of CK cases from WGS data. Collectively, these results support paired tumor-normal WGS as a single comprehensive assay well suited for AML diagnostics according to current classification and risk-stratification systems, while refining assessment of TP53 allelic state and karyotypic complexity.
Open AccessWhole-genome sequencing enables improved AML diagnostics and refines assessment of TP53 allelic state and complex karyotype
Accurate genetic characterization is central to modern acute myeloid leukemia (AML) diagnostics, yet current standard-of-care (SoC) testing relies on multiple complementary assays. We compared paired tumor-normal whole-genome sequencing (WGS) with SoC diagnostics in a population-based cohort of 109 adult AML patients, assessing variant detection, disease classification according to ICC 2022 and WHO 2022, and risk stratification according to ELN 2022. WGS showed high concordance with SoC across variant classes. When considering all reported SoC variants together with high-confidence WGS variants as true positives, WGS showed equal to higher sensitivity than SoC for single-nucleotide variants and small insertions/deletions (97% vs 92%), structural variants (SVs; 100% vs 87%), and copy-number alterations (CNAs; 88.5% both). WGS identified clinically important lesions missed by SoC in 16 cases (15%), including FLT3-ITDs and KMT2A, NUP98 and MECOM rearrangements. Classification and risk assignments were 95-96% concordant, with WGS-driven reclassifications in 4-5% of cases, primarily through detection of cryptic SVs and myelodysplasia-related lesions. Integrated analysis of genomic alterations, including copy-neutral loss-of-heterozygosity, refined TP53 allelic state assessment and demonstrated increased genomic complexity in AML with biallelic TP53 alterations. We developed a supervised machine-learning model for complex karyotype (CK) probability, based on WGS-derived copy-number and SV burden, enabling automated identification of CK cases from WGS data. Collectively, these results support paired tumor-normal WGS as a single comprehensive assay well suited for AML diagnostics according to current classification and risk-stratification systems, while refining assessment of TP53 allelic state and karyotypic complexity.
- Open Access
Ultra-Sensitive DNA-Based NPM1 Mutation Detection Using superRCA on Flow Cytometry
Background: NPM1 mutations are established biomarkers for measurable residual disease (MRD) monitoring in acute myeloid leukemia (AML). RT-qPCR is widely used for NPM1 MRD assessment, but sensitive DNA-based methods offer advantages in sample stability and workflow. superRCA is a novel mutation detection technology that combines genotyping with rolling circle amplification to convert target molecules into fluorescent particles that can be enumerated by flow cytometry. Here, we evaluated the performance of superRCA for detection of the most common NPM1 variants, MutA, MutB, and MutD. Methods: Analytical performance was assessed by determining limit of blank (LoB), limit of detection (LoD), limit of quantification (LoQ), precision, linearity, and cross-reactivity. Method comparison was performed using 83 biobanked clinical samples from patients with NPM1 MutA-positive AML previously analyzed by RT-qPCR, qPCR, ddPCR, and deep sequencing. Correlation, agreement, and positive and negative percent agreement (PPA/NPA) versus RT-qPCR were evaluated. Results: The superRCA assay demonstrated LoD below 0.005% variant allele frequency (VAF) for all three NPM1 variants. Linearity was tested and demonstrated over 0.01–10.24% VAF. superRCA showed strong correlation with the other methods. Using LoD as the positivity threshold, PPA and NPA versus RT-qPCR detectable signal were 64% and 100%, respectively; using LoB, PPA was 89% and NPA 92%. Several superRCA-positive samples were negative by lower-input DNA methods. Conclusions: superRCA introduces ultra-sensitive molecular testing by combining sequence-specific DNA genotyping and flow cytometric enumeration. The NPM1 superRCA assay demonstrated low background, high sensitivity, precision, and broad linearity, with strong correlation with established molecular methods. These findings support further evaluation of superRCA for NPM1 MRD monitoring in AML.
Open AccessUltra-Sensitive DNA-Based NPM1 Mutation Detection Using superRCA on Flow Cytometry
Background: NPM1 mutations are established biomarkers for measurable residual disease (MRD) monitoring in acute myeloid leukemia (AML). RT-qPCR is widely used for NPM1 MRD assessment, but sensitive DNA-based methods offer advantages in sample stability and workflow. superRCA is a novel mutation detection technology that combines genotyping with rolling circle amplification to convert target molecules into fluorescent particles that can be enumerated by flow cytometry. Here, we evaluated the performance of superRCA for detection of the most common NPM1 variants, MutA, MutB, and MutD. Methods: Analytical performance was assessed by determining limit of blank (LoB), limit of detection (LoD), limit of quantification (LoQ), precision, linearity, and cross-reactivity. Method comparison was performed using 83 biobanked clinical samples from patients with NPM1 MutA-positive AML previously analyzed by RT-qPCR, qPCR, ddPCR, and deep sequencing. Correlation, agreement, and positive and negative percent agreement (PPA/NPA) versus RT-qPCR were evaluated. Results: The superRCA assay demonstrated LoD below 0.005% variant allele frequency (VAF) for all three NPM1 variants. Linearity was tested and demonstrated over 0.01–10.24% VAF. superRCA showed strong correlation with the other methods. Using LoD as the positivity threshold, PPA and NPA versus RT-qPCR detectable signal were 64% and 100%, respectively; using LoB, PPA was 89% and NPA 92%. Several superRCA-positive samples were negative by lower-input DNA methods. Conclusions: superRCA introduces ultra-sensitive molecular testing by combining sequence-specific DNA genotyping and flow cytometric enumeration. The NPM1 superRCA assay demonstrated low background, high sensitivity, precision, and broad linearity, with strong correlation with established molecular methods. These findings support further evaluation of superRCA for NPM1 MRD monitoring in AML.
- Top Cited Papers
- 2 April 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (14) , 1532-1561
Diagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel
The European LeukemiaNet has periodically issued guidelines for the diagnosis and management of acute myeloid leukemia (AML) in adults. These consensus recommendations, most recently updated in 2022, incorporate recent advances in genomic testing, disease detection methods, target identification, and response assessment. Although similarities exist between AML in children and adults, pediatric AML is frequently characterized by unique cytogenetic and molecular features, which require distinct genetic and immunophenotypic diagnostics, therapeutic approaches, response assessment criteria, and supportive care strategies. To address these specific needs, an international panel of pediatric hematologist-oncologists, biologists, geneticists, and laboratory medicine scientists convened to develop recommendations for the diagnosis and management of AML in children, adolescents, and young adults (hereafter termed pediatric AML) that are discussed in this special report.
- 2 April 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (14) , 1532-1561
Top Cited PapersDiagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel
The European LeukemiaNet has periodically issued guidelines for the diagnosis and management of acute myeloid leukemia (AML) in adults. These consensus recommendations, most recently updated in 2022, incorporate recent advances in genomic testing, disease detection methods, target identification, and response assessment. Although similarities exist between AML in children and adults, pediatric AML is frequently characterized by unique cytogenetic and molecular features, which require distinct genetic and immunophenotypic diagnostics, therapeutic approaches, response assessment criteria, and supportive care strategies. To address these specific needs, an international panel of pediatric hematologist-oncologists, biologists, geneticists, and laboratory medicine scientists convened to develop recommendations for the diagnosis and management of AML in children, adolescents, and young adults (hereafter termed pediatric AML) that are discussed in this special report.
- Open Access
- 8 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-14
The genomic landscape of relapsed infant and childhood KMT2A-rearranged acute leukemia
To study the mechanisms of relapse in KMT2A-rearranged (KMT2A-r) acute lymphoblastic (ALL) and acute myeloid leukemia (AML), we performed whole-genome and exome sequencing of infants and children with relapsed ALL/AML (n = 36), and longitudinal deep-sequencing of 257 samples in 30 patients. Somatic alterations in drug-response genes, most commonly in TP53 and IKZF1 (64%), were highly enriched in early relapse ALL (79%, 9-36 months after diagnosis), but rare in very early relapse ALL (KMT2A-r ALL and AML evade therapy differently and provide insights into the mechanisms of relapse in this highly lethal form of pediatric acute leukemia.
- 8 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-14
Open AccessThe genomic landscape of relapsed infant and childhood KMT2A-rearranged acute leukemia
To study the mechanisms of relapse in KMT2A-rearranged (KMT2A-r) acute lymphoblastic (ALL) and acute myeloid leukemia (AML), we performed whole-genome and exome sequencing of infants and children with relapsed ALL/AML (n = 36), and longitudinal deep-sequencing of 257 samples in 30 patients. Somatic alterations in drug-response genes, most commonly in TP53 and IKZF1 (64%), were highly enriched in early relapse ALL (79%, 9-36 months after diagnosis), but rare in very early relapse ALL (KMT2A-r ALL and AML evade therapy differently and provide insights into the mechanisms of relapse in this highly lethal form of pediatric acute leukemia.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
Supplementary Table 1. List of genes assessed by copy number analysis on WES data.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
Supplementary Table 1. List of genes assessed by copy number analysis on WES data.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
Supplementary Figure 2. Diagnostic yield criterion-based when all patients fulfilling CytoMol criterion (n=39) are assigned to CytoMol regardless of whether they were included in the study based on another criteria. MH: medical history; FH: family history; S-FH: strong family history; CytoMol: inclusion due to findings in the somatic profiling; P: Pathogenic; LP: likely pathogenic; VUS: variant of unknown significance.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
Supplementary Figure 2. Diagnostic yield criterion-based when all patients fulfilling CytoMol criterion (n=39) are assigned to CytoMol regardless of whether they were included in the study based on another criteria. MH: medical history; FH: family history; S-FH: strong family history; CytoMol: inclusion due to findings in the somatic profiling; P: Pathogenic; LP: likely pathogenic; VUS: variant of unknown significance.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
Supplementary Figure 5. Overall survival in patients with AML (A) or MDS (B) based on whether a P/LP germline variant in a well-established gene for hereditary blood disorders was found (“Yes”, blue line) or not (“No”, grey line). Comparison among subgroups was performed using the Log-rank test, with the resulting p-value presented within the plot.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
Supplementary Figure 5. Overall survival in patients with AML (A) or MDS (B) based on whether a P/LP germline variant in a well-established gene for hereditary blood disorders was found (“Yes”, blue line) or not (“No”, grey line). Comparison among subgroups was performed using the Log-rank test, with the resulting p-value presented within the plot.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
Supplementary Table 2. List of genes that have been proposed to be associated with HHM during the study time.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
Supplementary Table 2. List of genes that have been proposed to be associated with HHM during the study time.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
Supplementary Figure 3. Pedigrees and Relative telomere length (TL) in two patients with a missense VUS in TERT measured by qPCR in peripheral blood leukocytes as previously described.1 The reference percentiles were determined from telomere length analysis of blood leukocytes from 283 healthy subjects (0–78 years of age). The curves shown depict the first, 10th, 50th, 90th, and 99th normal percentiles at each age, where the 50th percentile represents the mean. A) Patient GH01_P11 was included due to cytopenias, premature graying of hair, infections, skin hypomelanosis. The variant segregated in the mother, who did not show clinical signs of telomere biology disorders but displayed shorter TL. B) Patient GH01_P33 was included due to MDS, lung fibrosis, premature graying of hair. The family history was positive for lung fibrosis on paternal side and for leukemia and premature graying of hair on the maternal side. Segregation analysis in parental samples was not possible. Reference: 1. Norberg A, Rosén A, Raaschou-Jensen K, et al: Novel variants in Nordic patients referred for genetic testing of telomere-related disorders. Eur J Hum Genet 26:858–867, 2018
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
Supplementary Figure 3. Pedigrees and Relative telomere length (TL) in two patients with a missense VUS in TERT measured by qPCR in peripheral blood leukocytes as previously described.1 The reference percentiles were determined from telomere length analysis of blood leukocytes from 283 healthy subjects (0–78 years of age). The curves shown depict the first, 10th, 50th, 90th, and 99th normal percentiles at each age, where the 50th percentile represents the mean. A) Patient GH01_P11 was included due to cytopenias, premature graying of hair, infections, skin hypomelanosis. The variant segregated in the mother, who did not show clinical signs of telomere biology disorders but displayed shorter TL. B) Patient GH01_P33 was included due to MDS, lung fibrosis, premature graying of hair. The family history was positive for lung fibrosis on paternal side and for leukemia and premature graying of hair on the maternal side. Segregation analysis in parental samples was not possible. Reference: 1. Norberg A, Rosén A, Raaschou-Jensen K, et al: Novel variants in Nordic patients referred for genetic testing of telomere-related disorders. Eur J Hum Genet 26:858–867, 2018
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
Supplementary Table 4. Pairwise Comparisons of Survival Outcomes using cox proportional hazards regression. The figure in main manuscript or supplementary materials showing the Kaplan-Meier analysis for the same comparison is also indicated. * indicates when HR could not be calculated due to lack of events in one of the groups being compared.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
Supplementary Table 4. Pairwise Comparisons of Survival Outcomes using cox proportional hazards regression. The figure in main manuscript or supplementary materials showing the Kaplan-Meier analysis for the same comparison is also indicated. * indicates when HR could not be calculated due to lack of events in one of the groups being compared.